Browse All

Current Filters

CLEAR FILTER x

TITLE

The Effects of Lecanemab Treatment on Soluble CSF Aß Protofibrils (PF) in Clarity AD

The Lecanemab Clarity AD Open-label Extension in Early Alzheimer’s Disease: Initial Findings from the 48-month Analysis

Baseline Characteristics and Preliminary Safety from a Multicenter, Safety Surveillance Study of Lecanemab Treatment for Alzheimer’s Disease in Real-world Clinical Practice Using Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) Registry